glp 1 agonist novo nordisk Ozempic's patent problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite GLP-1 RA education

GLOWs value is structural skin work collagen rebuilding, microvascular support, and organized cell migration in a single vial: Collagen rebuilding and matrix quality

Compared to mice with normal Gls1 expression, Gls1-deficient mice exhibited a significant increase in overall survival after radiotherapy, and their levels of natural killer cells and interferon alpha/gamma proteins were significantly higher than those of mice with normal Gls1 expression

Next, metabolites were quantified by comparison to an eight-point quantification curve of metabolite standards

By application, the building and construction segment has held a major market share of 39% in 2024

GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes